Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Invested Capital: 2020-2025

Historic Invested Capital for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $724.7 million.

  • Maravai Lifesciences Holdings' Invested Capital fell 36.12% to $724.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724.7 million, marking a year-over-year decrease of 36.12%. This contributed to the annual value of $873.1 million for FY2024, which is 33.55% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Invested Capital of $724.7 million as of Q3 2025, which was down 4.88% from $761.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Invested Capital ranged from a high of $1.4 billion in Q4 2022 and a low of $724.7 million during Q3 2025.
  • For the 3-year period, Maravai Lifesciences Holdings' Invested Capital averaged around $1.1 billion, with its median value being $1.3 billion (2024).
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Invested Capital spiked by 59.31% in 2022 and then slumped by 41.17% in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Invested Capital (Quarterly) stood at $1.1 billion in 2021, then skyrocketed by 33.15% to $1.4 billion in 2022, then declined by 8.28% to $1.3 billion in 2023, then tumbled by 33.55% to $873.1 million in 2024, then slumped by 36.12% to $724.7 million in 2025.
  • Its Invested Capital was $724.7 million in Q3 2025, compared to $761.9 million in Q2 2025 and $825.2 million in Q1 2025.